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Alendronate release from calcium 
phosphate cement for bone 
regeneration in osteoporotic 
conditions
Claire I. A. van Houdt1,2, Paulo R. Gabbai-Armelin3,4, Paula M. Lopez-Perez1, 
Dietmar J. O. Ulrich2, John A. Jansen1, Ana Claudia M. Renno3,4 & Jeroen J. J. P. van den 
Beucken  1
Osteoporosis represents a major health problem in terms of compromising bone strength and 
increasing the risk of bone fractures. It can be medically treated with bisphosphonates, which act 
systemically upon oral or venous administration. Further, bone regenerative treatments in osteoporotic 
conditions present a challenge. Here, we focused on the development of a synthetic bone substitute 
material with local diminishing effects on osteoporosis. Composites were created using calcium 
phosphate cement (CPC; 60 wt%) and polylactic-co-glycolic acid (PLGA; 40 wt%), which were loaded 
with alendronate (ALN). In vitro results showed that ALN-loaded CPC/PLGA composites presented 
clinically suitable properties, including setting times, appropriate compressive strength, and controlled 
release of ALN, the latter being dependent on composite degradation. Using a rat femoral condyle bone 
defect model in osteoporotic animals, ALN-loaded CPC/PLGA composites demonstrated stimulatory 
effects on bone formation both within and outside the defect region.
Osteoporosis is the most frequent human metabolic bone disorder affecting over 75 million people in Europe, 
Japan and the USA1. As such, osteoporosis represents a major health problem in terms of compromising bone 
strength and increasing the risk of bone fractures2. In patients suffering from osteoporosis, the bone healing 
process is negatively influenced3, which challenges the treatment of bone defects or bone fractures. Bone grafting 
is a widely-used therapy to reconstruct bone defects, although it remains a challenging problem particularly for 
compromised conditions such as osteoporosis. Autologous bone transplantation can be employed to regenerate 
bone defects, but its use is hampered by the need for additional surgical procedures and potential limitations in 
bone quality and quantity. Alternatively, the use of allografts and xenografts is related to immunological issues 
and an increased risk of cross-species disease transmission4,5. In contrast, the use of synthetic biomaterials as a 
bone substitute has many advantages, including off-the-shelf availability in various shapes and sizes. Still, the bio-
logical performance of synthetic bone substitutes is inferior to autologous bone6. Consequently, optimization of 
the biological performance of synthetic bone substitutes via e.g. the release of biologically active factors is a highly 
explored field within bone biomaterials research7.
Osteoporosis is characterized by reduced bone mineral density causing lower bone mass and deterioration 
of bone tissue micro-architecture. This results from an imbalance between the continuous bone formation and 
resorption during bone remodeling and an altered variety of proteins in the extracellular matrix of the bone8,9. 
Osteoporosis is primarily observed after menopause in women, with increasing age in both women and men 
(ratio of 2:1), or secondary by chronic predisposing medical problems10. World-wide life expectancy has increased 
over the last couple of decades for both men and women, resulting in an aging population1,2,11,12. This increase in 
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elderly people is expected to continue, ultimately resulting in a further increased need of reliable bone grafting 
materials for elderly, osteoporotic patients.
The most prescribed medication for osteoporosis are bisphosphonates13. The regular route of administration 
is oral, for which it has been observed that 24 h excretion levels by the renal system reach percentages of 38% 
to 73%14. The major disadvantage of oral administration of bisphosphonates is their poor absorption from the 
gastro-intestinal tract, generally less than 1%15. This is futher negatively influenced when the stomach contains 
food or has the presence of calcium15. The bisphosphonate fraction remaining in the body predominantly local-
izes to areas with high bone turnover by exploiting its affinity to mineral within the bone extracellular matrix. 
After localizing to these areas, bisphosphonates can remain within the bone for many years. Among the different 
types of bisphosphonates, ALN and risedronate are frequently chosen because these both increase bone mineral 
density, reduce the risk of fracture, and are well tolerated16.
In view of the aforementioned, optimization of synthetic bone substitutes with bisphosphonates to locally adjust 
the imbalance in bone remodeling seems a straightforward approach to aid bone regeneration in osteoporotic condi-
tions. Among the currently available synthetic bone substitutes, calcium phosphate (CaP) based materials are inorganic 
biomaterials that show high similarity to bone tissue by resembling the mineral phase of bone and are already popular 
implant materials in several fields of surgery17. Calcium phosphate cement (CPC) represents a suitable scaffold material 
for bone regenerative treatment18,19. CPC has the advantage of being injectable and moldable, for which it allows perfect 
filling directly into a bone defect or by pre-setting it in a specifically designed mold fitted to the defect requirements. 
When adding porogens, (e.g. poly(lactic-co-glycolic acid) (PLGA) microspheres) to CPC, controlled degradation of 
the material can be obtained as well as the possibility to release bioactive agents, e.g. osteoinductive growth factors or 
therapeutic drugs18,20. Previous in vitro studies proved a successful incorporation of bisphosphonates into ceramic bone 
substitutes21–33. Generally, these studies showed altered but still acceptable material properties, steady release of the 
bisphosphonate with inhibition of osteoclasts and stimulation of osteoblast. Only a few reported on ceramic implants 
used in vivo34–37. These all showed positive results of the material on bone formation.
Here, we used the anti-osteoporotic drug ALN to functionalize CPC/PLGA. We characterized the material 
morphologically and crystallographically, analyzed setting time and mechanical properties, and determined ALN 
release kinetics. In addition, we used a femoral condyle bone defect model in osteoporotic rats to comparatively 
evaluate the biological performance of ALN-loaded CPC/PLGA. We hypothesized that loading CPC/PLGA com-
posites with ALN would (i) not critically affect material morphology and crystallography, (ii) promote controlled 
ALN release, and hence (iii) enhance the biological performance of CPC/PLGA in osteoporotic conditions by 
increasing bone formation rate and volumes.
Results
Material characterization. After mixing both CPC and CPC/PLGA materials with ALN, all formula-
tions remained injectable using standard syringes. Setting times (Fig. 1A) of CPC and CPC/PLGA formulations 
showed to range from 4 to 28 min for initial and from 8 to 58 min for final setting. ALN loading via the liquid 
phase significantly increased setting times of both CPC and CPC/PLGA formulations. For subsequent in vitro 
experiments, we chose ALN doses of 0.5 wt% (low dose) and 5.0 wt% (high dose), which respectively presented 
initial setting times of ~10–12 min and ~20–22 min for both CPC formulations.
Figure 2 shows SEM micrographs for all CPC formulations. PLGA could be discriminated due to morphologi-
cal and size differences compared to the CPC matrix. The composites presented a homogenous aspect with PLGA 
particles dispersed throughout the CPC matrix (Fig. 2B,D and F).
FTIR analysis (Fig. 1B) showed absorption peaks representative for α-TCP and PLGA. A strong peak of car-
bonyl at ~1750 cm−1 was detected in PLGA containing samples, while representative peaks for PO4−3 at the range 
of 900 to 1100 cm−1 were observed for all formulations. Due to low crystallinity of ALN, no characteristic peaks 
were observed for this component.
XRD patterns of the composites at day 0 (after setting) showed an initial phase transition from α-TCP to 
hydroxyapatite (HA; Fig. 1C; dashed lines) for CPC-blank, CPC-lowALN, CPC/PLGA-blank and α-CPC/
PLGA-lowALN. After 3 and 7 days of incubation, peaks for HA formation were observed (at ~26 and 31.8 °2θ; 
Fig. 1D), but no HA peaks were observed for CPC-highALN and CPC/PLGA-highALN, indicating that phase 
transformation was not taking place for high ALN formulations. This pattern was also observed after 148 days 
(data not shown).
The compressive strength for CPC and CPC/PLGA formulations assessed by mechanical test ranged from 
~4 to 6 MPa (Fig. 1E). The addition of ALN to CPC or CPC/PLGA tended to decrease the compressive strength 
for CPC and CPC/PLGA formulations. Statistical differences were found for CPC-blank compared to CPC/
PLGA-highALN (p = 0.0115).
ALN release kinetics. The ALN release data assessed via ninhydrin assay showed negligible ALN release for 
CPC-formulations (Fig. 3). In contrast, the CPC/PLGA formulations showed a 2-week lag phase with negligible 
release followed by a biphasic ALN release with 2 distinct sustained release phases. A first fast and sustained ALN 
release from day 15 to 42 (~0.02 and ~0.20 mg ALN/day for low and highALN, respectively) reached ~15% (~0.7 mg) 
and 20% (~10 mg) of the initially loaded ALN amount for CPC/PLGA-lowALN and CPC/PLGA-highALN, respec-
tively. Thereafter, a second sustained release phase with lower ALN release was observed (~9.40 × 10−4 and ~0.02 mg 
ALN/day for low and highALN, respectively), which after 148 days cumulatively reached ~16% (~0.8 mg) and 25% 
(~12.0 mg) of the initially loaded ALN amount for CPC/PLGA low and high dosages, respectively.
Based on the in vitro data of ALN incorporation into CPC and CPC/PLGA, we proceeded with in vivo 
analysis using only degradable CPC/PLGA, since no ALN release was detected from CPC. Additionally, CPC/
PLGA-highALN was excluded for in vivo studies, as it showed incomplete phase transformation (based on setting 
time and physicochemical analysis).
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Biological performance. Micro-CT analysis. The micro-CT data were reconstructed to 3D representa-
tions and then sliced to obtain an internal view of the bone defects. A representative overview with sagittal, 
frontal and transversal slices through the defect region for each experimental group is presented in Fig. 4A. Color 
settings were adjusted to distinguish between different densities of bone and material. After 4 and 12 weeks, both 
CPC/PLGA-blank and CPC/PLGA-lowALN showed presence of CPC in contact with surrounding bone tissue. 
With implantation time, both CPC/PLGA-blank and CPC/PLGA-lowALN showed more bone formation around 
the composites.
Descriptive histology. Representative images of the histological sections of specimens embedded in pMMA are 
depicted in Fig. 4B. In general, histological analysis showed differential material degradation and bone forma-
tion depending on the composition of the implant. For CPC/PLGA-blank and CPC/PLGA-lowALN, no appar-
ent degradation was visible at 4 weeks, and peripheral degradation was observed after 12 weeks. There was an 
increased amount of bone formation, macroscopically, around the composites for CPC/PLGA-lowALN com-
pared to CPC/PLGA-blank. Similar as with the micro-CT images, this difference was more apparent after 12 
weeks. The histological slides of CPC/PLGA-lowALN further showed an apparently higher bone density outside 
the ROI. At higher magnification (Fig. 4C), newly formed bone in direct contact with CPC/PLGA-blank and 
CPC/PLGA-lowALN was observed. Within the ROI, both CPC/PLGA-blank and CPC/PLGA-low ALN showed 
that bone had reached the center of the ROI.
Bone dynamics by fluorochrome labeling. Incorporation of fluorochrome labels into newly formed bone 
(Fig. 5A) was observed for calcein green (green; week 4), alizarine complexone (red; week 6) and rolitetracycline 
(yellow; week 8). However, none of the sections showed incorporation of calcein blue (blue; week 2). For both 
Figure 1. (A–E) Characterization analysis for CPC/PLGA-ALN composites. (A) initial and final setting time 
at different ALN wt%, dashed lines indicate the initial setting time at 5 wt% ALN for CPC and CPC/PLGA, 
ap < 0.05 comparing CPC initial setting time with CPC/PLGA initial setting time; (B) FTIR of Alendronic acid, 
PLGA, CPC, CPC-highALN and CPC/PLGA-highALN. Dashed lines indicate peaks associated to PLGA (C=O 
stretching) and CPC (PO4−3 bending) in the materials. (C,D) XRD at days 0 and 7 for the materials, dashed 
lines indicate HA peaks (26 and 31.8 °2θ); (E) compressive strength, bp < 0.05 for CPC-blank compared to CPC/
PLGA-highALN. Error bars represent the SD.
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CPC/PLGA-blank and CPC/PLGA-lowALN, calcein green was mostly present within the ROI (Fig. 5B). This was 
significantly more for CPC/PLGA-blank compared to CPC/PLGA-lowALN (p < 0.05). However, in the periph-
eral area of 2.5 to 3 mm from the center of the ROI (Fig. 5C), CPC/PLGA-lowALN showed significantly higher 
presence of calcein green compared to CPC/PLGA-blank (p < 0.05). Bone formation dynamics by fluorescent 
microscopy showed that significantly more bone was formed near the center of the defect at 12 weeks for CPC/
PLGA-lowALN compared to CPC/PLGA-blank (p < 0.01; Fig. 5D).
Histomorphometrical analysis. Histomorphometry data (Fig. 6) showed CPC remnants within the ROI after 
4 weeks of 74.2 ± 5.7% for CPC/PLGA-blank and 71.7 ± 5.4% for CPC/PLGA-lowALN. After 12 weeks, CPC 
Figure 2. (A–F) Micrographs obtained by SEM. (A) CPC-blank. (B) CPC/PLGA-blank. (C) CPC-lowALN. (D) 
CPC/PLGA-lowALN. (E) CPC-highALN and (F) CPC/PLGA-highALN. Asterisks and arrows indicate CPC 
and PLGA particles respectively. Magnification of 500×.
Figure 3. (A,B) Cumulative alendronate release from CPC and CPC/PLGA cylinders loaded with the 
bisphosphonate for up to 148 days. (A) Absolute ALN release (mg). (B) Relative ALN release (% of loaded 
dose). Error bars represent the SD.
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remnants within the ROI were 60.7 ± 8.9% for CPC/PLGA-blank and 66.5 ± 7.1% for CPC/PLGA-lowALN. 
Statistical analysis showed significant temporal decrease from 4 to 12 weeks of material remnants was seen for 
CPC/PLGA-blank (p < 0.05), but not for CPC/PLGA-lowALN (p > 0.05).
Figure 4. (A–C): (A) Representative micro-CT images of each experimental group. Color settings were 
adjusted to distinguish between different densities of bone and material, coloring bone yellow and CPC/PLGA 
purple. Representative histological images of pMMA sections for each experimental group with images at (B) 
4 weeks and 12 weeks and (C) corresponding images at high magnification; methylene blue and basic fuchsine 
staining; red arrows] new bone (pink color); *CPC/PLGA; BM] bone marrow (blue color).
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Bone areas within the ROI after 4 weeks were 4.1 ± 1.4% for CPC/PLGA-blank and 5.5 ± 1.4% for CPC/
PLGA-lowALN. After 12 weeks, bone areas within the ROI were 22.8 ± 8.0% for CPC/PLGA-blank and 
16.4 ± 4.1% for CPC/PLGA-lowALN. Statistical analysis for bone area within ROI showed no significant differ-
ence between CPC/PLGA-blank and CPC/PLGA-lowALN for both time points (p > 0.05). Data showed signif-
icant temporal increase from 4 to 12 weeks of bone for CPC/PLGA-blank and CPC/PLGA-lowALN (Student’s 
t-test, both p < 0.001).
Descriptive histology suggested increased bone formation outside the ROI, therefore, bone areas were 
also measured in an extended ROI (eROI, from 2.5 to 3 mm). After 4 weeks bone area outside the ROI were 
17.3 ± 2.0% for CPC/PLGA-blank and 15.5 ± 3.7% for CPC/PLGA-lowALN. Bone area for the eROI after 12 
weeks, were 10.9 ± 1.8% for CPC/PLGA-blank and 18.1 ± 2.1% for CPC/PLGA-lowALN. Statistical analysis for 
Figure 5. (A–D): (A) Representative fluorochrome microscopy images at 12 weeks, with high magnification 
images; red box] area of high magnification; green color] calcein green (week 4); red color] alizarine 
complexone (week 6); yellow color] rolitetracycline (week 8). (B–D): Relative volume areas (mean + SD) of 
fluorochrome labels in contact with concentric circles for calcein green (week 4), alizarine complexone (week 6) 
and rolitetracycline (week 8) for both CPC/PLGA-blank and CPC/PLGA-lowALN (B) within ROI (0–2.5 mm) 
and (C) extended ROI (eROI, 2.5–3 mm); statistical analysis showed significantly more calcein green within 
ROI for CPC/PLGA-blank compared to CPC/PLGA-lowALN (Student’s t-test, p < 0.05); analysis showed 
significantly more calcein green in the eROI for CPC/PLGA-lowALN compared to CPC/PLGA-blank (Student’s 
t-test, p < 0.05); (D) Distance of the first ring that is in contact with a fluorochrome (mean + SD) for both CPC/
PLGA-blank and CPC/PLGA-lowALN; statistical analysis showed significantly closer contact with calcein green 
for CPC/PLGA-blank compared to CPC/PLGA-lowALN (Student’s t-test, p < 0.01); Range] 0 to 55 rings, edge 
of defect] ring 45 (2.5 mm from centre).
Labels Descriptions
CPC-blank Only α-TCP
CPC-lowALN α-TCP + 0.5 wt % ALN
CPC-highALN α-TCP + 5.0 wt % ALN
CPC/PLGA-blank 60% α-TCP/40% PLGA
CPC/PLGA-lowALN 60% α-TCP/40% PLGA + 0.5 wt % ALN
CPC/PLGA-highALN 60% α-TCP/40% PLGA + 5.0 wt % ALN
Table 1. Labels and descriptions of the experimental groups.
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bone area for the eROI showed significantly more bone at 12 weeks there was significantly more bone for CPC/
PLGA-lowALN compared to CPC/PLGA-blank (Student’s t-test, p < 0.05). Data showed significant temporal 
increase from 4 to 12 weeks of bone only for CPC/PLGA-lowALN (Student’s t-test, p < 0.01). There was signifi-
cantly less bone formation outside the ROI for CPC/PLGA-blank at 12 weeks compared to at 4 weeks (p < 0.001).
Discussion
The aim of this study was to develop CPC/PLGA composites loaded with ALN and investigate the morpho-
logical features, physicochemical properties and ALN release kinetics. Furthermore, we evaluated the efficacy 
of CPC and CPC/PLGA as a local ALN release system in a rat femoral condyle bone defect in osteoporotic 
rats. We hypothesized that addition of ALN would (i) not critically affect material physicochemical properties, 
(ii) promote controlled ALN release, and (iii) enhance the biological performance of the CPC for bone regen-
eration in osteoporotic rats. We showed that ALN loading increased CPC and CPC/PLGA setting times and 
marginally affected compressive strength. Loading ALN at a dose of 5 wt% impeded with the conversion of the 
alpha-TCP base powder to HA within 3 days of incubation in PBS, while a dose of 0.5 wt% did not. ALN release 
kinetics showed hardly any release from CPC, whereas CPC/PLGA showed a controlled release of ALN up to 
148 days with 2 consecutive sustained release phases following a 2-week lag phase. The main in vivo findings by 
micro-CT imaging, descriptive histology and quantitative histomorphometry showed that loading of ALN within 
CPC/PLGA did not increase bone formation within the defect region, but enhanced bone formation within the 
peri-defect region compared to control CPC/PLGA.
Previous in vitro studies proved a successful incorporation of bisphosphonates into ceramic bone sub-
stitutes21–32. These studies showed decrease of the mechanical properties and increases the setting time of the 
ceramic, however the range was still within acceptable limits21,26,31,32. This is consistent with our study and 
dependent of dose of the bisphosphonate added. By in vitro analysis the previous studies showed the release of 
the drug to be generally steady and not cytotoxic21,22,27–29,31,32. Moreover, there was a inhibition of osteoclasts 
and stimulation of osteoblasts22–27,29,30. Most of these studies also used ALN, however there were different ways 
of incorporation the drug into the cement. Most of the studies used the technique of loading the drug onto the 
surface of an inorganic implant by soaking the implant in a solution containing the drug21–25,28–32. However, 
this technique has the disadvantage of limited drug loading content and results in a uncontrolled burst release 
on administration38. The study by Panzavolta et al. incorporated the drug (both ALN and pamidronate) into 
Figure 6. Accumulated volume percentages (mean ± SD) of new bone formation (green bars for eROI and blue 
bars within ROI) and material remnants (grey bars) at 4 and 12 weeks after implantation for CPC/PLGA-blank 
and CPC/PLGA-lowALN; statistical analysis showed significant increase of bone formation within ROI from 4 
to 12 weeks for both CPC/PLGA-blank and CPC/PLGA-lowALN (***p < 0.001, **p < 0.01); bone formation 
over time in the eROI significantly decreased for CPC/PLGA-blank (p < 0.001), but significantly increased for 
CPC/PLGA-lowALN (p < 0.001); material remnants significantly decreased for CPC/PLGA-blank (*p < 0.05) 
but not significantly for CPC/PLGA-lowALN (ns = p > 0.05); aAt 12 weeks there was a significant higher 
amount of bone in the eROI for CPC/PLGA-lowALN compared to CPC/PLGA-blank (p < 0.05).
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the liquid phase, they do not report on the release properties26. In the study by Shi et al. the ALN was incorpo-
rated into the liquid phase of PLGA which was then incorporated as a porogen into the cement27. Their results 
showed a controlled release which is in concurrence with our study. There are previous in vivo studies using a 
cement enhanced with bisphophonate, showing positive results on bone formation34–37. However, a fair compar-
ison between these four studies is compromised, due to use of all different cements in combination with other 
bisphosphonates and also the animal models were different.
For clinical application, handling properties of injectable bone substitutes that harden in situ are of utmost 
importance. Alterations in the composition of CPC or CPC/PLGA have shown to affect important handling prop-
erties, including injectability39 and setting time40,41. Here, addition of ALN into the liquid phase of the cement 
formulation make it possible to obtain injectable materials that were extruded by standard syringes42, which cor-
roborates previous work43. For setting time evaluation, we used systematic increases of ALN loading (0.5–6 wt%) 
and observed clinically acceptable initial setting times (i.e. <20 min)19 for ALN amounts up to 5 wt%. ALN act on 
the CPC hydration process which is a reaction of dissolution-precipitation of CPC particles and Ca2+/PO4−3 ions 
respectively, affecting the curing of CPC43. In view of eventual clinical application, CPC/PLGA composites with 
low (0.5 wt%) and high (5.0 wt%) doses of ALN were subsequently used for further experimental in vitro work. As 
a less important characteristic for injectable bone substitutes meant for application under minimal loading, ALN 
loading showed marginal lowering effects on compressive strength. Panzavolta et al.44 and Li et al.45 also demon-
strated a lowering effect of ALN on the CPC compressive strength, but with values of ~5.0 MPa these remain close 
to those of human cancellous bone45.
From a material perspective, FTIR analysis and XRD confirmed the conversion of the alpha-TCP base powder 
to HA formed through hydration (HA, JCPDS 01-074-0566)46 within 3 days of incubation in PBS for CPC and 
CPC/PLGA formulations without or low ALN loading. In contrast, high ALN loading inhibited this conversion. 
It is well-known that α-TCP hydrolyses to hydroxyapatite through dissolution and successive precipitation of the 
more stable phase, and the high affinity of ALN for calcium ions retards this process43.
ALN release kinetics showed negligible release from CPC, whereas CPC/PLGA showed a controlled release of 
ALN with 2 distinct consecutive sustained release phases after a 2-week lag phase. Apparently, the dense configu-
ration of the CPC and related lack of degradation is responsible for the observed negligible ALN release. Similarly, 
the relatively dense CPC/PLGA composite configuration upon setting limits ALN release during a 2-week lag 
phase. Subsequently, sustained ALN release coincides with the generation of a porous network within the ceramic 
matrix due to PLGA degradation. The second sustained ALN release phase takes place after PLGA degradation 
from ~day 40 onwards, when liquid can penetrate the ceramic matrix via an interconnective porosity system47. 
The difference in average daily ALN relative release (~20 and ~10 times greater in the 1st compared to 2nd phase 
for CPC-lowALN and CPC-highALN, respectively) is likely due to the additional acidifying effect of PLGA deg-
radation products in the 1st phase, while a sole dissolution-controlled release process from a porous ceramic 
matrix remains thereafter48,49. Our observations are in accordance with those of Panyam and coworkers50, who 
studied the use of PLGA micro- and nanoparticles for drug-delivery, and previous work from our group using 
CPC/PLGA as a drug-delivery vehicle51,52.
Over the last decade, several studies examined the effect of bisphosphonates on peri-implant bone response 
using metallic bone implants53–66 and showed enhanced bone formation (using mainly ALN and zolendronate) 
compared to controls without bisphosphonate, with evaluation periods up to one year59. This is in accordance 
with our results, which showed enhanced peri-defect bone formation in response to locally released ALN from 
CPC/PLGA composites. However, these studies differ in the use of non-degradable metallic implants versus 
degradable CPC/PLGA in our study. Remarkably, we did not observe any influence of ALN loading on bone 
formation within the defect region, for which the reason remains unclear.
CPC has the advantage as a bone substitute material of being injectable and moldable, allowing to directly 
adapt or being pre-set to the shape of a bone defect18,19. For this study we used pre-set composite of CPC/PLGA 
with and without ALN, specifically shaped to the measurements of our defect. With these pre-set CPC/PLGA 
composites we aimed to ensure the implants contained consistent amounts of cement and alendronate for both 
our in vitro and in vivo studies, as well as reduce operative time.
Conclusion
This study showed by in vitro analysis that ALN-loaded CPC/PLGA presents clinically acceptable handling, suit-
able compressive strength, and a controlled ALN release. The in vivo bone defect model showed that a relative low 
dose of ALN (0.5 wt%) signifcantly increases bone formation in the peri-defect region in osteoporotic conditions, 
without effects on CPC/PLGA degradation. The data suggest that future clinical application of ALN-loaded CPC/
PLGA could be benificial for bone healing in compromised conditions.
Materials and Methods
Materials. Alpha tri-calcium phosphate (α-TCP) was provided by Cam Bioceramics B.V. (mean particle 
~4.0 µm; Leiden, The Netherlands). Poly(DL-lactic-co-glycolic acid) PLGA particles (containing both a lactic 
and glycolic weight percentage of 50%; particle size ~60 µm) was obtained from Corbion (PLGA, Purasorb®, 
Gorinchem, The Netherlands). Carboxymethylcellulose (CMC) was purchased from Kelco (Georgia, USA) and 
alendronate (ALN) was purchased from AK Scientific (Union City, California, USA).
Preparation of CPC/PLGA and CPC/PLGA-ALN composites. CPC/PLGA composites were prepared by weigh-
ing 0.597 g of α-TCP, 0.398 g of PLGA and 0.005 g of CMC in a beaker. Subsequently, the liquid component (4% 
NaH2PO4 solution) was added in a liquid/power ratio of 0.50 and the composition was mixed with a spatula. 
Afterwards, the composite was injected, using a 2 ml syringe (BD Plastipakt, Becton Dickinson S.A., Madrid, 
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Spain), into teflon molds to obtain cylinders of 5 mm × 3 mm (diameter and height) for in vitro analysis. For 
mechanical tests, cylinders of 6 mm × 12 mm (diameter and height) were prepared utilizing different molds.
ALN was introduced into CPC/PLGA scaffolds via the liquid CPC component. Briefly, ALN was dissolved in 
4% NaH2PO4 at different concentrations (range: 0–6 wt% for setting time investigations) and the pH was adjusted 
to ~7.4. The selected experimental groups are presented in Table 1.
For in vivo experiments, pre-set cylindrical CPC/PLGA composites (2.5 mm in diameter and 5 mm in height) 
were prepared, either or not containing ALN (2 μg/ml for the CPC/PLGA-lowALN) within the liquid component. 
This concentration corresponds to 0.5 wt.% ALN. After setting for 24 h at room temperature, composites were 
removed from the mold and sterilized using ethylene oxide (Synergy Health, Venlo, The Netherlands).
Material characterization. Setting time. The setting time of CPC-formulations was determined using the 
Gillmore needle method at 37 °C, as described previously (ASTM C266, 1999)67. For this purpose, a bronze block 
containing six holes was used as a mold (6 mm in diameter, 12 mm in height). The different formulations (n = 3) 
were inserted into the mold in order to assess the initial and final setting.
Morphology. Immediately after setting, the samples were mounted on stubs with carbon tape and sputter coated 
with gold. SEM (SEM, JEOL 6310) was performed to examine the structural morphology of the composites.
Physico-chemical analysis. Immediately after preparation and setting, the samples were pulverized and submit-
ted to Fourier transform infrared spectroscopy (FTIR; Perkin-Elmer 1700, UK). FTIR was performed to charac-
terize the chemical bonds present in the samples. Analyses were done using pulverized samples in the range of 
520–4000 cm−1 with a resolution of 2 cm−1. The samples were scanned 100 times for each FTIR measurement and 
the spectrum acquired was the average of all these scans.
X-ray diffraction (XRD, Cu-Ka, 45 kV, 30 mA, Philips BV, the Netherlands) patterns of pulverized samples 
were collected (2θ range: 20–40°) to crystallographically characterize the phases. XRD evaluation was done at 
days 0, 3, 7 and 148 after incubation in 1.0 ml of phosphate buffered saline solution (PBS; pH 7.4).
Mechanical testing. After setting, the compressive strength (CS) of the CPC cylinders was measured, in the lon-
gitudinal direction of the specimens, at a loading rate of 1 mm/min using a testing bench machine (Model 858, 
Mini-Bionix II, MTS Systems Corp., Eden Prairie, MN, USA) using three cylinders per experimental group (n = 3).
ALN release from CPC/PLGA-ALN composites. In vitro release tests were performed by soaking one sample cyl-
inder of each CPC formulation in 1.0 ml of PBS and incubating the samples (n = 3) under agitating conditions at 
37 °C. ALN release was determined using a ninhydrin assay on releasates collected after selected time periods (range: 
1–148 days)68. Briefly, 100 µL of releasate (complete removal of 1 ml and addition of 1 ml of fresh PBS) or standard 
(serial dilutions of ALN; range: 0–200 µM) was pipetted in a 96-well plate, after which 75 µL of ninhydrin color rea-
gent (Sigma-Aldrich, St. Louis, USA) was added for incubation at 80 °C for 30 min. Subsequently, the well plate was 
cooled and 100 µL of stabilizing solvent (50% ethanol) was added into each well. The absorbance of each well was 
measured on a microplate spectrophotometer at 570 nm (Bio-Tech Instruments, Winooski, VT, USA).
Biological performance. Animals. For this experiment, twelve healthy mature female Wistar rats were 
used at 3 months of age with an average weight of ~200 g. Animals were allowed to acclimatize for 7 days and 
housing was provided per pair in a standard macrolon type 3 cage. To induce an osteoporotic condition, rats 
were subjected to bilateral ovariectomy (OVX). All rats received two surgical procedures during the course of 
the experiment: OVX surgery and 6 weeks later bone defect surgery. After OVX surgery, a low calcium diet was 
provided during six weeks with pellets containing 0.01% calcium and 0.77% phosphorous (Ssniff Spezialdiäten 
GmbH, Soest, Germany). After the bone defect surgery, a standard rodent chow was provided ad libitum. The 
housing room was maintained under standard laboratory conditions (light-dark cycle: 12:12 h, temperature: 
20–22 °C, relative humidity: 45–55%). All experiments were conducted in accordance with institutional, national 
and international guidelines for animal care and the Dutch law concerning animal welfare. The studies were 
reviewed and approved by the Experimental Animal Committee of the Radboud University (RUDEC 2013-080).
Surgical procedure to induce osteoporotic conditions. All animals received OVX surgery through two separate inci-
sions in the lateral abdominal wall. The same procedure was followed as previously described by Alghamdi et al.69.
Surgical procedure to create and fill femoral bone defects. Six weeks after OVX surgery, a bone defect was cre-
ated in both femoral condyles of each animal. Alternating the left and right femur, CPC/PLGA-blank and CPC/
PLGA-lowALN, pre-set composites were used to fill the defects. Anesthesia was induced and maintained by Isoflurane 
inhalation (Rhodia Organique Fine Limited) combined with oxygen delivered by mask. Pre-operatively pain med-
ication was provided by an injection of Carprofen (Rimadyl®, Pfizer Animal Health, New York, USA) in dosage of 
5 mg/kg, given 15 min before surgery. For a minimum duration of 2 days postoperatively, Carprofen was given every 
24 h. Additionally, to diminish postoperative pain, Buprenorfine (Temgesic®, Reckitt Benckiser Health Care Limited, 
Schering-Plough, UK) was given every 12 h in a dosage of 0.01 mg/kg. Additionally, to ensure adequate postopera-
tive analgesia, before closing the wound local drop anaesthesia was provided by Lidocaïne (10 mg/ml Lidocaïne FNA, 
Centrafarm B.V., Etten-Leur, the Netherlands) and Bupivacaïne (5 mg/ml Bupivacaïne Actavis, Actavis B.V., Baarn, the 
Netherlands) diluted with NaCl using ~1 ml per rat containing 1 mg of Lidocaïne and 0.25 mg of Bupivacaïne.
Before creating femoral defects, both hind limbs of the rats were shaved and disinfected with povidone iodine. 
The rats were immobilized in supine position and with the knee maximally flexed a longitudinal incision through 
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skin and muscle was made on the medial surface. After exposure of the medial side of the distal femoral condyle, 
the knee capsule was incised. Then, the knee was extended to luxate the patella laterally. When a clear view of 
the knee joint was established, a bone defect (Ø 2.5 mm, depth 5 mm) was created longitudinal to the axis of the 
femur, using a dental drill (Elcomed 9927 SPS; W&H Dentalwerk Burmoos GmbH, Burmoos, Austria). A series 
of increasing bur diameters (1.5–2.0–2.3–2.5 mm) were used at a speed of maximum 5000 rpm and a constant 
cooling by dripping saline. The drilled cavity was then washed with saline and dried using sterile gauze.
Subsequently, the CPC/PLGA composites were alternatingly placed into the defect. A total of 24 implants were 
used, resulting in n = 6 per group. To increase statistical power paired analysis was made possible by combining 
CPC/PLGA-blank with CPC/PLGA-lowALN in each rat. After local drop anesthesia, the muscular tissue layer 
was closed with absorbable sutures (Vicryl® 4.0, Ethicon, Amersfoort, The Netherlands) after which the skin was 
closed by small staples (Agraven®; InstruVet BV, Cuijk, The Netherlands). In the initial postoperative period, 
the intake of water and food was monitored as well as the weight of the animals. In addition, the animals were 
observed for signs of pain, infection and proper activity and weighed again postoperatively once a week to iden-
tify significant weight loss (>20%) compared to preoperative body weight of each rat.
Fluorochrome labeling for bone dynamics analysis. Animals assigned to a 12-week implantation period received 
a series of four fluorochromes (SigmaAldrich; Munich, Germany) by subcutaneous injection with a 2-week inter-
val, starting two weeks after implantation surgery: Calcein blue (product no. M1255, dose 30 mg/kg; week 2), 
calcein green (C0875, 10 mg/kg; week 4), alizarine complexone red (A3882, 25 mg/kg; week 6) and rolitetra-
cycline yellow (R2253, 25 mg/kg; week 8). Before injection, the solutions were set to neutral pH (7.2–7.4), then 
filtered through a 0.22 sterile millipore filter, and finally checked for fluorescence.
Specimen retrieval. After implantation periods of 4 and 12 weeks, the animals were euthanized by suffocation 
with CO2. The femurs including the implanted materials were harvested, stripped from soft tissues and immedi-
ately fixed in 10% formalin solution. Using a diamond saw, the specimens were cut to become suitable for ex vivo 
micro-CT scanning and histological processing. After fixation, specimens were stored in 70% ethanol.
Micro-CT. A desktop X-ray micro-CT system was used (Skyscan-1072, TomoNT version 3 N.5, Skyscan®, 
Kontich, Belgium) for 3D imaging. The specimens were placed onto the sample holder with the long axis of the 
femur perpendicular to the scanning beam. 3D reconstruction and imaging processing was performed using 
NRecon V1.4 and CTvox v2.7 (Skyscan®, Kontich, Belgium), respectively.
Histological processing. After performing micro-CT scanning, the specimens were dehydrated in a graded series 
of ethanol (70%-100%), after which they were embedded in polymethylmethacrylate (pMMA). After polymeriza-
tion, thin sections of 10 μm were prepared in a cross-sectional direction perpendicular on the longitudinal direc-
tion of the defect using a diamond blade microtome (Leica Microsystems SP 1600, Nussloch, Germany) using a 
sawing technique as previously described69,70. Using this microtome sawing technique, at least three sections of 
~10 μm thick per specimen are cut with intermediate loss of ~300 μm (thickness of sawing blade). With this loss 
the sections are therefore 300 μm separated from each other. The first section of each specimen was aimed at the 
center of bone defect or slightly proximally and then continued distally on the femur. The bone defect was created 
at distal end of the femur with a diameter of 2.5 mm and depth of 5 mm (for further information also see section 
“Surgical procedure to create and fill femoral bone defects”). Three sections of each specimen were stained with 
methylene blue and basic fuchsine. For the 12-week group, 3 additional sections were made and left unstained 
for fluorescence analysis and immediately stored in the dark. All sectioning and histological processing was per-
formed at the Radboudumc, department of Biomaterials (Nijmegen, the Netherlands).
Descriptive histology and histomorphometrical analysis. At both implantation periods of 4 and 12 weeks, the pMMA 
histological sections (3 sections per specimen) were examined by light microscopy (Leica Microsystems AG, Wetzlar, 
Germany); non-stained images were used for fluorescence microscopy. Digital images of the sections were assessed his-
tologically and quantitative histomorphometry was performed using ImageJ computer-based image analysis software 
(Java® ImageJ 1.47, Image processing and analysis in Java)71. For quantitative analysis, a circular region of interest (ROI) 
with a diameter equal to the created defects (i.e. 2.5 mm) or an extended  ROI (eROI; 3 mm) were superimposed on the 
defect area. Within the ROI and eROI, the amounts of newly formed bone and material remnants were measured using 
a combination of color discrimination (staining) and morphological appearance (for verification).
Statistical analysis. Data are presented as mean with SD for characterization, bone dynamics by fluoro-
chorme labeling and histomorphometrical data. Statistical analyses were performed using STATISTICA 7.0 
(StatSoft, Tulsa, Oklahoma, USA) or GraphPad Software (PRISM; La Jolla CA, USA). Shapiro-Wilk normality 
test was used to check distribution. A Kruskal-Wallis test and Dunn post hoc were used for nonparametric data. 
One-way analysis of variance (ANOVA) and Tukey multiple comparisons post-tests were used for parametric 
data. Student’s t-tests were used for comparison of histomorphometrical data between time points for selected 
materials and paired t-tests were used for comparison between the two composites. Values of p < 0.05 were con-
sidered statistically significant.
References
 1. Prevention and management of osteoporosis. World Health Organization technical report series 921, 1–164, back cover (2003).
 2. Riggs, B. L. & Melton, L. J. 3rd The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 17, 505S–511S (1995).
 3. Kubo, T. et al. Osteoporosis influences the late period of fracture healing in a rat model prepared by ovariectomy and low calcium 
diet. The Journal of steroid biochemistry and molecular biology 68, 197–202 (1999).
www.nature.com/scientificreports/
1 1SCIENTIFIC RepORtS |  (2018) 8:15398  | DOI:10.1038/s41598-018-33692-5
 4. Greenwald, M. A., Kuehnert, M. J. & Fishman, J. A. Infectious disease transmission during organ and tissue transplantation. 
Emerging infectious diseases 18, e1, https://doi.org/10.3201/eid1808.120277 (2012).
 5. Greenwald, A. S. et al. Bone-graft substitutes: facts, fictions, and applications. The Journal of bone and joint surgery. American volume 
83(A Suppl 2 Pt 2), 98–103 (2001).
 6. Klijn, R. J., Meijer, G. J., Bronkhorst, E. M. & Jansen, J. A. A meta-analysis of histomorphometric results and graft healing time of 
various biomaterials compared to autologous bone used as sinus floor augmentation material in humans. Tissue Eng Part B Rev 16, 
493–507, https://doi.org/10.1089/ten.TEB.2010.0035 (2010).
 7. Agarwal, R. & Garcia, A. J. Biomaterial strategies for engineering implants for enhanced osseointegration and bone repair. Adv Drug 
Deliv Rev 94, 53–62, https://doi.org/10.1016/j.addr.2015.03.013 (2015).
 8. Fini, M. et al. A new austenitic stainless steel with a negligible amount of nickel: an in vitro study in view of its clinical application in 
osteoporotic bone. Journal of biomedical materials research. Part B, Applied biomaterials 71, 30–37, https://doi.org/10.1002/
jbm.b.30068 (2004).
 9. Finigan, J. Bone up on osteoporosis. Nursing standard 17, 104, https://doi.org/10.7748/ns2003.09.17.51.104.c3449 (2003).
 10. Fitzpatrick, L. A. Secondary causes of osteoporosis. Mayo Clin Proc 77, 453–468, https://doi.org/10.4065/77.5.453 (2002).
 11. Anderson, G. F. & Hussey, P. S. Population aging: a comparison among industrialized countries. Health affairs 19, 191–203 (2000).
 12. Blume, S. W. & Curtis, J. R. Medical costs of osteoporosis in the elderly Medicare population. Osteoporosis international: a journal 
established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the 
USA 22, 1835–1844, https://doi.org/10.1007/s00198-010-1419-7 (2011).
 13. Duque, G. Osteoporosis in older persons: current pharmacotherapy and future directions. Expert Opin Pharmacother 14, 
1949–1958, https://doi.org/10.1517/14656566.2013.822861 (2013).
 14. Russell, R. G., Watts, N. B., Ebetino, F. H. & Rogers, M. J. Mechanisms of action of bisphosphonates: similarities and differences and 
their potential influence on clinical efficacy. Osteoporosis international: a journal established as result of cooperation between the 
European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 19, 733–759, https://doi.org/10.1007/
s00198-007-0540-8 (2008).
 15. Ezra, A. & Golomb, G. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv 
Drug Deliv Rev 42, 175–195 (2000).
 16. G, D. In Expert Opin Pharmacother Vol. 14, 1949–1958 (2013).
 17. Dorozhkin, S. V. Calcium orthophosphates: occurrence, properties, biomineralization, pathological calcification and biomimetic 
applications. Biomatter 1, 121–164, https://doi.org/10.4161/biom.18790 (2011).
 18. Habraken, W. J., Wolke, J. G., Mikos, A. G. & Jansen, J. A. PLGA microsphere/calcium phosphate cement composites for tissue 
engineering: in vitro release and degradation characteristics. Journal of biomaterials science. Polymer edition 19, 1171–1188, https://
doi.org/10.1163/156856208785540136 (2008).
 19. Komath, M. & Varma, H. K. Development of a fully injectable calcium phosphate cement for orthopedic and dental applications. 
Bulletin of Materials Science 26, 415–422, https://doi.org/10.1007/Bf02711186 (2003).
 20. Felix Lanao, R. P., Leeuwenburgh, S. C., Wolke, J. G. & Jansen, J. A. Bone response to fast-degrading, injectable calcium phosphate 
cements containing PLGA microparticles. Biomaterials 32, 8839–8847, https://doi.org/10.1016/j.biomaterials.2011.08.005 
(2011).
 21. Denissen, H., van Beek, E., Lowik, C., Papapoulos, S. & van den Hooff, A. Ceramic hydroxyapatite implants for the release of 
bisphosphonate. Bone Miner 25, 123–134 (1994).
 22. Josse, S. et al. Novel biomaterials for bisphosphonate delivery. Biomaterials 26, 2073–2080, https://doi.org/10.1016/j.
biomaterials.2004.05.019 (2005).
 23. Seshima, H. et al. Control of bisphosphonate release using hydroxyapatite granules. Journal of biomedical materials research. Part B, 
Applied biomaterials 78, 215–221, https://doi.org/10.1002/jbm.b.30446 (2006).
 24. Boanini, E., Torricelli, P., Gazzano, M., Giardino, R. & Bigi, A. Alendronate-hydroxyapatite nanocomposites and their interaction 
with osteoclasts and osteoblast-like cells. Biomaterials 29, 790–796, https://doi.org/10.1016/j.biomaterials.2007.10.040 (2008).
 25. Boanini, E., Torricelli, P., Gazzano, M., Fini, M. & Bigi, A. The effect of alendronate doped calcium phosphates on bone cells activity. 
Bone 51, 944–952, https://doi.org/10.1016/j.bone.2012.07.020 (2012).
 26. Panzavolta, S., Torricelli, P., Bracci, B., Fini, M. & Bigi, A. Alendronate and Pamidronate calcium phosphate bone cements: setting 
properties and in vitro response of osteoblast and osteoclast cells. J Inorg Biochem 103, 101–106, https://doi.org/10.1016/j.
jinorgbio.2008.09.012 (2009).
 27. Shi, X., Wang, Y., Ren, L., Gong, Y. & Wang, D. A. Enhancing alendronate release from a novel PLGA/hydroxyapatite microspheric 
system for bone repairing applications. Pharm Res 26, 422–430, https://doi.org/10.1007/s11095-008-9759-0 (2009).
 28. Capra, P. et al. A preliminary study on the morphological and release properties of hydroxyapatite-alendronate composite materials. 
J Microencapsul 28, 395–405, https://doi.org/10.3109/02652048.2011.576783 (2011).
 29. Schnitzler, V. et al. Investigation of alendronate-doped apatitic cements as a potential technology for the prevention of osteoporotic 
hip fractures: critical influence of the drug introduction mode on the in vitro cement properties. Acta Biomater 7, 759–770, https://
doi.org/10.1016/j.actbio.2010.09.017 (2011).
 30. Zhang, X., Hu, J., Li, Y., Yin, G. & Luo, E. Effects of ibandronate-hydroxyapatite on resorptive activity of osteoclasts. Arch Med Sci 7, 
53–60, https://doi.org/10.5114/aoms.2011.20604 (2011).
 31. Gong, T. et al. Preparation, characterization, release kinetics, and in vitro cytotoxicity of calcium silicate cement as a risedronate 
delivery system. Journal of biomedical materials research. Part A 102, 2295–2304, https://doi.org/10.1002/jbm.a.34908 (2014).
 32. Pascaud, P. et al. Adsorption on apatitic calcium phosphates for drug delivery: interaction with bisphosphonate molecules. J Mater 
Sci Mater Med 25, 2373–2381, https://doi.org/10.1007/s10856-014-5218-0 (2014).
 33. Faucheux, C. et al. Controlled release of bisphosphonate from a calcium phosphate biomaterial inhibits osteoclastic resorption in 
vitro. Journal of biomedical materials research. Part A 89, 46–56, https://doi.org/10.1002/jbm.a.31989 (2009).
 34. Matuszewski, L. et al. Effect of implanted bisphosphonate-enriched cement on the trabecular microarchitecture of bone in a rat 
model using micro-computed tomography. Int Orthop 37, 1187–1193, https://doi.org/10.1007/s00264-013-1855-z (2013).
 35. Verron, E. et al. Vertebroplasty using bisphosphonate-loaded calcium phosphate cement in a standardized vertebral body bone 
defect in an osteoporotic sheep model. Acta Biomater 10, 4887–4895, https://doi.org/10.1016/j.actbio.2014.07.012 (2014).
 36. Gong, T. et al. Osteogenic and anti-osteoporotic effects of risedronate-added calcium phosphate silicate cement. Biomed Mater 11, 
045002, https://doi.org/10.1088/1748-6041/11/4/045002 (2016).
 37. Ma, J. H., Guo, W. S., Li, Z. R. & Wang, B. L. Local Administration of Bisphosphonate-soaked Hydroxyapatite for the Treatment of 
Osteonecrosis of the Femoral Head in Rabbit. Chin Med J (Engl) 129, 2559–2566, https://doi.org/10.4103/0366-6999.192768 
(2016).
 38. Cattalini, J. P., Boccaccini, A. R., Lucangioli, S. & Mourino, V. Bisphosphonate-based strategies for bone tissue engineering and 
orthopedic implants. Tissue Eng Part B Rev 18, 323–340, https://doi.org/10.1089/ten.TEB.2011.0737 (2012).
 39. Habraken, W. J., Wolke, J. G., Mikos, A. G. & Jansen, J. A. Injectable PLGA microsphere/calcium phosphate cements: physical 
properties and degradation characteristics. Journal of biomaterials science. Polymer edition 17, 1057–1074 (2006).
 40. Renno, A. C. et al. Incorporation of bioactive glass in calcium phosphate cement: material characterization and in vitro degradation. 
Journal of biomedical materials research. Part A 101, 2365–2373, https://doi.org/10.1002/jbm.a.34531 (2013).
www.nature.com/scientificreports/
1 2SCIENTIFIC RepORtS |  (2018) 8:15398  | DOI:10.1038/s41598-018-33692-5
 41. Klijn, R. J. et al. Three different strategies to obtain porous calcium phosphate cements: comparison of performance in a rat skull 
bone augmentation model. Tissue engineering. Part A 18, 1171–1182, https://doi.org/10.1089/ten.TEA.2011.0444 (2012).
 42. Bohner, M. & Baroud, G. Injectability of calcium phosphate pastes. Biomaterials 26, 1553–1563, https://doi.org/10.1016/j.
biomaterials.2004.05.010 (2005).
 43. Shen, Z., Yu, T. & Ye, J. Microstructure and properties of alendronate-loaded calcium phosphate cement. Mater Sci Eng C Mater Biol 
Appl 42, 303–311 https://doi.org/10.1016/j.msec. 2014.05. 043 (2014).
 44. Panzavolta, S., Torricelli, P., Bracci, B., Fini, M. & Bigi, A. Functionalization of biomimetic calcium phosphate bone cements with 
alendronate. J Inorg Biochem 104, 1099–1106, https://doi.org/10.1016/j.jinorgbio.2010.06.008 (2010).
 45. Li, Y. H. et al. The biocompatibility of calcium phosphate cements containing alendronate-loaded PLGA microparticles in vitro. 
Experimental biology and medicine 240, 1465–1471, https://doi.org/10.1177/1535370215579142 (2015).
 46. Kumar, S. A. Eco-Friendly Nano-Hybrid Materials for Advanced Engineering Applications (Apple Academic Press, 2016).
 47. Lodoso-Torrecilla, I. et al. Multimodal pore formation in calcium phosphate cements. Journal of biomedical materials research. Part 
A 106, 500–509, https://doi.org/10.1002/jbm.a.36245 (2018).
 48. Tung, I. C. In vitro drug release of antibiotic-loaded porous hydroxyapatite cement. Artif Cells Blood Substit Immobil Biotechnol 23, 
81–88, https://doi.org/10.3109/10731199509117669 (1995).
 49. Mitra, A. K., Kwatra, D. & Vadlapudi, A. D. Drug Delivery (Jones & Bartlett Learning, LLC, 2014).
 50. Panyam, J. et al. Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-co-glycolide) nano- and 
microparticles. J Control Release 92, 173–187, https://doi.org/10.1016/S0168-3659(03)00328-6 (2003).
 51. Felix Lanao, R. P. et al. RANKL delivery from calcium phosphate containing PLGA microspheres. Journal of biomedical materials 
research. Part A 101, 3123–3130, https://doi.org/10.1002/jbm.a.34623 (2013).
 52. Felix Lanao, R. P. et al. Porous calcium phosphate cement for alveolar bone regeneration. Journal of tissue engineering and 
regenerative medicine 8, 473–482, https://doi.org/10.1002/term.1546 (2014).
 53. Kurth, A. H. et al. The bisphosphonate ibandronate improves implant integration in osteopenic ovariectomized rats. Bone 37, 
204–210, https://doi.org/10.1016/j.bone.2004.12.017 (2005).
 54. McKenzie, K., Dennis Bobyn, J., Roberts, J., Karabasz, D. & Tanzer, M. Bisphosphonate remains highly localized after elution from 
porous implants. Clinical orthopaedics and related research 469, 514–522, https://doi.org/10.1007/s11999-010-1527-x (2011).
 55. Tanzer, M., Karabasz, D., Krygier, J. J., Cohen, R. & Bobyn, J. D. The Otto Aufranc Award: bone augmentation around and within 
porous implants by local bisphosphonate elution. Clinical orthopaedics and related research 441, 30–39 (2005).
 56. Peter, B. et al. Local delivery of bisphosphonate from coated orthopedic implants increases implants mechanical stability in 
osteoporotic rats. Journal of biomedical materials research. Part A 76, 133–143, https://doi.org/10.1002/jbm.a.30456 (2006).
 57. McLeod, K. et al. Adsorption of bisphosphonate onto hydroxyapatite using a novel co-precipitation technique for bone growth 
enhancement. Journal of biomedical materials research. Part A 79, 271–281, https://doi.org/10.1002/jbm.a.30792 (2006).
 58. Jakobsen, T. et al. Local bisphosphonate treatment increases fixation of hydroxyapatite-coated implants inserted with bone 
compaction. J Orthop Res 27, 189–194, https://doi.org/10.1002/jor.20745 (2009).
 59. Bobyn, J. D., McKenzie, K., Karabasz, D., Krygier, J. J. & Tanzer, M. Locally delivered bisphosphonate for enhancement of bone 
formation and implant fixation. The Journal of bone and joint surgery. American volume 91(Suppl 6), 23–31, https://doi.org/10.2106/
JBJS.I.00518 (2009).
 60. Jakobsen, T., Baas, J., Bechtold, J. E., Elmengaard, B. & Soballe, K. The effect on implant fixation of soaking tricalcium phosphate 
granules in bisphosphonate. The open orthopaedics journal 6, 371–375, https://doi.org/10.2174/1874325001206010371 (2012).
 61. Bobyn, J. D. et al. Local alendronic acid elution increases net periimplant bone formation: a micro-CT analysis. Clinical orthopaedics 
and related research 472, 687–694, https://doi.org/10.1007/s11999-013-3120-6 (2014).
 62. Meraw, S. J., Reeve, C. M. & Wollan, P. C. Use of alendronate in peri-implant defect regeneration. Journal of periodontology 70, 
151–158, https://doi.org/10.1902/jop.1999.70.2.151 (1999).
 63. Niu, S. et al. Peri-implant and systemic effects of high-/low-affinity bisphosphonate-hydroxyapatite composite coatings in a rabbit 
model with peri-implant high bone turnover. BMC musculoskeletal disorders 13, 97, https://doi.org/10.1186/1471-2474-13-97 (2012).
 64. Linderback, P., Areva, S., Aspenberg, P. & Tengvall, P. Sol-gel derived titania coating with immobilized bisphosphonate enhances 
screw fixation in rat tibia. Journal of biomedical materials research. Part A 94, 389–395, https://doi.org/10.1002/jbm.a.32708 
(2010).
 65. Peter, B. et al. Calcium phosphate drug delivery system: influence of local zoledronate release on bone implant osteointegration. 
Bone 36, 52–60, https://doi.org/10.1016/j.bone.2004.10.004 (2005).
 66. Alghamdi, H. S. et al. Synergistic effects of bisphosphonate and calcium phosphate nanoparticles on peri-implant bone responses in 
osteoporotic rats. Biomaterials 35, 5482–5490, https://doi.org/10.1016/j.biomaterials.2014.03.069 (2014).
 67. ASTM. Standard Test Method for Time of Setting of Hydraulic-Cement Paste by Gillmore Needles, Document Number: ASTM 
C266–99, ASTM International (1999).
 68. Taha, E. A. & Youssef, N. F. Spectrophotometric determination of some drugs for osteoporosis. Chemical & Pharmaceutical Bulletin 
51, 1444–1447, https://doi.org/10.1248/cpb.51.1444 (2003).
 69. Alghamdi, H. S., van den Beucken, J. J. & Jansen, J. A. Osteoporotic rat models for evaluation of osseointegration of bone implants. 
Tissue engineering. Part C, Methods 20, 493–505, https://doi.org/10.1089/ten.TEC.2013.0327 (2014).
 70. van der Lubbe, H. B., Klein, C. P. & de Groot, K. A simple method for preparing thin (10 microM) histological sections of 
undecalcified plastic embedded bone with implants. Stain Technol 63, 171–176 (1988).
 71. Lopez-Heredia, M. A. et al. Bone formation analysis: effect of quantification procedures on the study outcome. Tissue engineering. 
Part C, Methods 18, 369–373, https://doi.org/10.1089/ten.TEC.2011.0353 (2012).
Acknowledgements
The authors would like to acknowledge ms. N. van Dijk for her assistance with the histological sectioning and 
fluorochrome labeling, dr. V. Cuijpers for his assistance on the ex vivo micro-CT and histological imaging and 
dr. ing. Bronkhorst for his with statistical and methodological guidance. The author P. R. Gabbai-Armelin would 
like to acknowledge the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Fundação 
de Amparo à Pesquisa do Estado de São Paulo (FAPESP) for the scholarships (grants no. 209507/2013-6 and 
2015/20704-8 respectively).
Author Contributions
Authors Claire I.A. van Houdt and Paulo R. Gabbai-Armelin equally contributed in writing of the main 
manuscript text. Paula M. Lopez-Perez aided in the in vitro part of this study. Ana Claudia M. Renno and Jeroen 
J.J.P. van den Beucken supervised both the experimental analysis and the writing of the manuscript. All authors 
reviewed the manuscript. All the listed authors have agreed to all of the contents.
www.nature.com/scientificreports/
13SCIENTIFIC RepORtS |  (2018) 8:15398  | DOI:10.1038/s41598-018-33692-5
Additional Information
Competing Interests: The authors declare no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2018
